1
|
Stuart T, Jeang WJ, Slivicki RA, Brown BJ, Burton A, Brings VE, Alarcón-Segovia LC, Agyare P, Ruiz S, Tyree A, Pruitt L, Madhvapathy S, Niemiec M, Zhuang J, Krishnan S, Copits BA, Rogers JA, Gereau RW, Samineni VK, Bandodkar AJ, Gutruf P. Wireless, Battery-Free Implants for Electrochemical Catecholamine Sensing and Optogenetic Stimulation. ACS Nano 2023; 17:561-574. [PMID: 36548126 DOI: 10.1021/acsnano.2c09475] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
Abstract
Neurotransmitters and neuromodulators mediate communication between neurons and other cell types; knowledge of release dynamics is critical to understanding their physiological role in normal and pathological brain function. Investigation into transient neurotransmitter dynamics has largely been hindered due to electrical and material requirements for electrochemical stimulation and recording. Current systems require complex electronics for biasing and amplification and rely on materials that offer limited sensor selectivity and sensitivity. These restrictions result in bulky, tethered, or battery-powered systems impacting behavior and that require constant care of subjects. To overcome these challenges, we demonstrate a fully implantable, wireless, and battery-free platform that enables optogenetic stimulation and electrochemical recording of catecholamine dynamics in real time. The device is nearly 1/10th the size of previously reported examples and includes a probe that relies on a multilayer electrode architecture featuring a microscale light emitting diode (μ-LED) and a carbon nanotube (CNT)-based sensor with sensitivities among the highest recorded in the literature (1264.1 nA μM-1 cm-2). High sensitivity of the probe combined with a center tapped antenna design enables the realization of miniaturized, low power circuits suitable for subdermal implantation even in small animal models such as mice. A series of in vitro and in vivo experiments highlight the sensitivity and selectivity of the platform and demonstrate its capabilities in freely moving, untethered subjects. Specifically, a demonstration of changes in dopamine concentration after optogenetic stimulation of the nucleus accumbens and real-time readout of dopamine levels after opioid and naloxone exposure in freely behaving subjects highlight the experimental paradigms enabled by the platform.
Collapse
Affiliation(s)
- Tucker Stuart
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - William J Jeang
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Richard A Slivicki
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Bobbie J Brown
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Alex Burton
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Victoria E Brings
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Lilian C Alarcón-Segovia
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
| | - Prophecy Agyare
- Department of Neuroscience, Northwestern University, Evanston, Illinois 60201, United States
| | - Savanna Ruiz
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Amanda Tyree
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Lindsay Pruitt
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Surabhi Madhvapathy
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
| | - Martin Niemiec
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - James Zhuang
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
| | - Siddharth Krishnan
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
| | - Bryan A Copits
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - John A Rogers
- Department of Materials Science and Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois 60201, United States
- Department of Mechanical Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Department of Biomedical Engineering, Northwestern University, Evanston, Illinois 60201, United States
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Evanston, Illinois 60201, United States
- Department of Neurological Surgery, Northwestern University, Evanston, Illinois 60208, United States
- Center for Bio-Integrated Electronics, Northwestern University, Evanston, Illinois 60208, United States
| | - Robert W Gereau
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Department of Neuroscience, Washington University, St. Louis, Missouri 63110, United States
- Department of Biomedical Engineering, Washington University, St. Louis, Missouri 63110, United States
| | - Vijay K Samineni
- Department of Anesthesiology, Washington University School of Medicine, St. Louis, Missouri 63110, United States
- Washington University Pain Center, Washington University School of Medicine, St. Louis, Missouri 63110, United States
| | - Amay J Bandodkar
- Department of Electrical and Computer Engineering, North Carolina State University, Raleigh, North Carolina 27606, United States
- Center for Advanced Self-Powered Systems of Integrated Sensors and Technologies (ASSIST), North Carolina State University, Raleigh, North Carolina 27606, United States
| | - Philipp Gutruf
- Department of Biomedical Engineering, University of Arizona, Tucson, Arizona 85721, United States
- Department of Electrical and Computer Engineering, University of Arizona, Tucson, Arizona 85721, United States
- Bio5 Institute, University of Arizona, Tucson, Arizona 85721, United States
- Neuroscience GIDP, University of Arizona, Tucson, Arizona 85721, United States
| |
Collapse
|
2
|
Slivicki RA, Yi J, Brings VE, Huynh PN, Gereau RW. The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of central nervous system activity with repeated dosing. Pain 2022; 163:1603-1621. [PMID: 34961756 PMCID: PMC9281468 DOI: 10.1097/j.pain.0000000000002550] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Accepted: 11/24/2021] [Indexed: 11/25/2022]
Abstract
ABSTRACT Activation of cannabinoid receptor type 1 (CB 1 ) produces analgesia in a variety of preclinical models of pain; however, engagement of central CB 1 receptors is accompanied by unwanted side effects, such as psychoactivity, tolerance, and dependence. Therefore, some efforts to develop novel analgesics have focused on targeting peripheral CB 1 receptors to circumvent central CB 1 -related side effects. In the present study, we evaluated the effects of acute and repeated dosing with the peripherally selective CB 1 -preferring agonist CB-13 on nociception and central CB 1 -related phenotypes in a model of inflammatory pain in mice. We also evaluated cellular mechanisms underlying CB-13-induced antinociception in vitro using cultured mouse dorsal root ganglion neurons. CB-13 reduced inflammation-induced mechanical allodynia in male and female mice in a peripheral CB 1 -receptor-dependent manner and relieved inflammatory thermal hyperalgesia. In cultured mouse dorsal root ganglion neurons, CB-13 reduced TRPV1 sensitization and neuronal hyperexcitability induced by the inflammatory mediator prostaglandin E 2 , providing potential mechanistic explanations for the analgesic actions of peripheral CB 1 receptor activation. With acute dosing, phenotypes associated with central CB 1 receptor activation occurred only at a dose of CB-13 approximately 10-fold the ED 50 for reducing allodynia. Strikingly, repeated dosing resulted in both analgesic tolerance and CB 1 receptor dependence, even at a dose that did not produce central CB 1 -receptor-mediated phenotypes on acute dosing. This suggests that repeated CB-13 dosing leads to increased CNS exposure and unwanted engagement of central CB 1 receptors. Thus, caution is warranted regarding therapeutic use of CB-13 with the goal of avoiding CNS side effects. Nonetheless, the clear analgesic effect of acute peripheral CB 1 receptor activation suggests that peripherally restricted cannabinoids are a viable target for novel analgesic development.
Collapse
Affiliation(s)
- Richard A. Slivicki
- Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO
| | - Jiwon Yi
- Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO
- Neuroscience Graduate Program, Division of Biology & Biomedical Sciences, Washington University School of Medicine, St. Louis, MO
| | - Victoria E. Brings
- Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO
| | - Phuong Nhu Huynh
- Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO
| | - Robert W. Gereau
- Washington University Pain Center and Department of Anesthesiology, Washington University School of Medicine, St. Louis, MO
- Department of Neuroscience, Washington University, St. Louis, MO
- Department of Biomedical Engineering, Washington University, St. Louis, MO
| |
Collapse
|
4
|
Rittiner JE, Brings VE, Zylka MJ. Overexpression of diacylglycerol kinase η enhances Gαq-coupled G protein-coupled receptor signaling. Mol Pharmacol 2014; 85:800-10. [PMID: 24608858 DOI: 10.1124/mol.113.091280] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Multiple genome-wide association studies have linked diacylglycerol kinase η (DGKη) to bipolar disorder (BPD). Moreover, DGKη expression is increased in tissue from patients with BPD. How increased levels of this lipid kinase might affect cellular functions is currently unclear. Here, we overexpressed mouse DGKη in human embryonic kidney 293 cells to examine substrate specificity and signaling downstream of endogenous G protein-coupled receptors (GPCRs). We found that DGKη can phosphorylate diacylglycerol (DAG) with different acyl side chains (8:0, 12:0, 18:1). In addition, overexpression of DGKη enhanced calcium mobilization after stimulating muscarinic receptors with carbachol and after stimulating purinergic receptors with ATP. This effect required DGKη catalytic activity, as assessed using a kinase-dead (G389D) mutant and multiple truncation constructs. DGKη was localized throughout the cytosol and did not translocate to the plasma membrane after stimulation with carbachol. Since protein kinase C (PKC) can be activated by DAG and promotes receptor desensitization, we also examined functional interactions between PKC and DGKη. We found that acute activation of PKC with phorbol 12-myristate 13-acetate shortened carbachol-evoked calcium responses and occluded the effect of overexpressed DGKη. Moreover, inhibition of PKC activity with bisindolylmaleimide I (BIM I) produced the same enhancing effect on carbachol-evoked calcium mobilization as overexpressed DGKη, and overexpression of DGKη produced no additional effect on calcium mobilization in the presence of BIM I. Taken together, our data suggest that DGKη enhances GPCR signaling by reducing PKC activation.
Collapse
Affiliation(s)
- Joseph E Rittiner
- Department of Cell Biology and Physiology, University of North Carolina Neuroscience Center, University of North Carolina, Chapel Hill, North Carolina
| | | | | |
Collapse
|